| Country Demographics ${ }^{\text {1,2,3,7 }}$ |  |
| :---: | :---: |
| Total population (2017) ${ }^{1}$ | 1618 |
| Urban population (\% of total, 2015) ${ }^{2}$ | 43\% |
| Health expenditure per capita (\$US, 2009) ${ }^{7}$ | \$1,866.55 |
| Health expenditure, total (\% of GDP, 2009) ${ }^{7}$ | 16.94\% |
| Total births (2017) ${ }^{1}$ | 19 |
| Surviving infants (2017) ${ }^{1}$ | 19 |
| Life expectancy at birth (years, 2001-06) ${ }^{7}$ | 71.6 yrs |
| Number of districts (2013) ${ }^{3}$ | 1 |


| HBsAg Prevalence $^{6}$  <br> Pre-vaccine HBsAG+ (\%) $8 \%$ <br> Liver Cancer as Cause of Cancer Death (in Men)  <br> Year: 2018 Ranking: NR  |
| :--- | :--- |

Page 1 of 2

| Hepatitis B Immunization Coverage ${ }^{4}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| HepB3 ${ }^{4}$ | 100\% | 100\% | 100\% | NR | 100\% | 86\% | 100\% | 99\% | 100\% | 100\% | 100\% | 99\% | 99\% | 100\% | NR | 100\% | 100\% | 100\% | 100\% |
| $\begin{aligned} & \text { HepB } \\ & \text { BD }^{4} \end{aligned}$ | 100\% | 100\% | 100\% | 100\% | 21\% | 9\% | 70\% | 99\% | 100\% | 100\% | 55\% | 100\% | 100\% | 100\% | NR | NR | NR | 84\% | 54\% |
| DTP3 ${ }^{4}$ | 100\% | 100\% | 100\% | NR | 100\% | 85\% | 100\% | 99\% | 100\% | 100\% | 100\% | 99\% | 99\% | 100\% | NR | 100\% | 100\% | 100\% | 100\% |
| BCG ${ }^{4}$ | 100\% | 100\% | 100\% | 100\% | 96\% | 97\% | 100\% | 99\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | NR | 100\% | NR | 100\% | 100\% |




## National Policies on Hepatitis B Immunization ${ }^{8}$

| Universal newborn HepB immunization (Y/N) ${ }^{8}$ | Y |
| :---: | :---: |
| - If Y , year introduced ${ }^{8}$ | 1986 |
| -HepB3 nationwide ${ }^{8}$ | NR |
| -Free for all newborns ( $\mathrm{Y} / \mathrm{N}$ ) <br> -If free, state year introduced: |  |
|  |  |
| Catch-up immunization program for unvaccinated children ( $\mathrm{Y} / \mathrm{N}$ ) |  |
| - If Y, year introduced <br> -Free for all unvaccinated children ( $\mathrm{Y} / \mathrm{N}$ ) -If free, state year introduced: |  |
|  |  |
|  |  |
| Immunization program for health care workers ( $\mathrm{Y} / \mathrm{N}$ ) <br> - If Y , year introduced <br> -Free for all health care workers( $\mathrm{Y} / \mathrm{N}$ ) <br> -If free, state year introduced: |  |
|  |  |
|  |  |
|  |  |
| HepB newborn immunization included in multiyear plan for EPI (Y/N) |  |
| HepB BD in schedule (Y/N) ${ }^{8}$ | Y |
| Systems to monitor HepB BD ${ }^{8}$ | Hospitals |
| Systems to deliver HepB BD ${ }^{8}$ | Hospitals |
| HepB vaccine funding other than country government ( $\mathrm{Y} / \mathrm{N}$ ) -If $Y$, please specify funding source: |  |
|  |  |

## National Policies on Chronic Hepatitis B Treatment

Treatment for chronic HBV infection covered (Y/N)

- If Y , year introduced
-Interferon ( $\mathrm{Y} / \mathrm{N}$ )
-Oral antiviral (Y/N)


## Certification Status ${ }^{1}$

| Year certification report received |  |
| :--- | :--- |
| Year certification panel convened | Nov 2015 |
| Year certification approved | Feb 2017 |
| Approved with prevalence <1\% or <2\%? | $<1 \%$ in children |

